In patients with low-grade UTUC
The OLYMPUS Study is ongoing. At the time of data cutoff1:
- 19 patients remained in CR
- 7 patients had disease recurrence
- 9 patients continued to be followed for 12-month duration of response1
|SCREENING||TREATMENT||FOLLOW-UP (POST-TREATMENT THERAPY AND EVALUATION)|
Primary endpoint: Complete response (CR)1
Secondary endpoint: Durability of response at 12-month follow-up of CR evaluation1
|PATIENT BASELINE CHARACTERISTICS IN THE OLYMPUS STUDY (N=71)|
|Age||Median 71 years||Range 42-87 years|
|Number of papillary tumors||Median 2*||Range 1-8|
|Diameter of largest papillary tumor||Median 8 mm||Range 5-15 mm|
|Unresectable tumors at baseline||48%|
|Prior history of low-grade UTUC||48%|
Every patient deserves a chance to spare their kidney for tomorrow
JELMYTO® is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC).
You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
Before receiving JELMYTO, tell your healthcare provider about all your medical conditions, including if you
How will I receive JELMYTO?
After receiving JELMYTO:
JELMYTO may cause serious side effects, including:
The most common side effects of JELMYTO include: side pain, urinary tract infection, blood in your urine, kidney problems, tiredness, nausea, stomach pain, trouble with urination, vomiting, low red blood cell count, frequent urination, itching, chills, and fever.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.
Please click here for JELMYTO Full Prescribing Information, including the Patient Information, for additional information.
Please click here for Full Prescribing Information, Instructions for Pharmacy and Instructions for Administration.